Mylan asks SCOTUS to end NHK-Fintiv rule
ricochet64 / Shutterstock.com
The European Patent Office (EPO) has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone (glatiramer acetate injection), in a win for Mylan.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
EPO, Copaxone, Mylan, patent invalidation, Teva, multiple sclerosis, Technical Board of Appeal, litigation, big pharma, commercial actions